Gilead Sciences | GILD - Selling And Administration Expenses

Stock Price
142.89
Daily Change
0.94 0.66%
Monthly
20.79%
Yearly
45.24%
Q1 Forecast
137.58

Gilead Sciences reported $1.35B in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Agios Pharmaceuticals USD 41.27M 4.6M Sep/2025
ALKERMES USD 171.77M 17.9M Sep/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
Amgen USD 1.7B 9M Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
Gilead Sciences USD 1.35B 6M Sep/2025
GlaxoSmithKline GBP 2.16B 19M Sep/2025
Glaxosmithkline GBP 2.91B 817.89M Sep/2025
Incyte USD 329.08M 1.94M Sep/2025
J&J USD 6.75B 831M Dec/2025
Merck USD 2.63B 0 Sep/2025
Moderna USD 268M 38M Sep/2025
Neurocrine Biosciences USD 291.6M 5.3M Sep/2025
Novartis USD 3.31B 134M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
PTC Therapeutics USD 84.05M 1.22M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
United Therapeutics USD 152M 60.5M Sep/2025
Vertex Pharmaceuticals USD 445.1M 20.5M Sep/2025